This proportion was significant or marginally significant for high-quality markers in half of the diseases (e.g., Alzheimer’s disease, colorectal neoplasms, amyotrophic lateral sclerosis) and significant for the low-quality markers in two datasets: Parkinson’s disease and amyotrophic lateral sclerosis.
← all excerpts
Overlooked poor-quality patient samples in sequencing data impair reproducibility of published clinically relevant datasets.
1
—
—